Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Notes Payables (2019 - 2025)

Pulmonx (LUNG) has disclosed Notes Payables for 7 consecutive years, with $105000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Notes Payables rose 6.06% to $105000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $105000.0, a 6.06% increase, with the full-year FY2024 number at $3.2 million, up 47.38% from a year prior.
  • Notes Payables was $105000.0 for Q3 2025 at Pulmonx, up from $104000.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $17.3 million in Q4 2021 to a low of $90000.0 in Q4 2022.
  • A 5-year average of $4.7 million and a median of $2.2 million in 2023 define the central range for Notes Payables.
  • Peak YoY movement for Notes Payables: tumbled 99.48% in 2022, then soared 5648.35% in 2024.
  • Pulmonx's Notes Payables stood at $17.3 million in 2021, then crashed by 99.48% to $90000.0 in 2022, then skyrocketed by 2294.44% to $2.2 million in 2023, then soared by 47.38% to $3.2 million in 2024, then crashed by 96.69% to $105000.0 in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Notes Payables are $105000.0 (Q3 2025), $104000.0 (Q2 2025), and $7.8 million (Q1 2025).